The Current Ratio as of November 2024 (TTM) for Puma Biotechnology, Inc. (PBYI) is 1.42

According to Puma Biotechnology, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.42. This represents a change of -1.51% compared to the average of 1.44 of the last 4 quarters.

Puma Biotechnology, Inc. (PBYI) Historical Current Ratio (quarterly & annually)

How has PBYI Current Ratio performed in the past?

The mean historical Current Ratio of Puma Biotechnology, Inc. over the last ten years is 2.91. The current 1.42 Current Ratio has changed 4.78% with respect to the historical average. Over the past ten years (40 quarters), PBYI's Current Ratio was at its highest in in the March 2015 quarter at 12.14. The Current Ratio was at its lowest in in the March 2021 quarter at 1.17.

Puma Biotechnology, Inc. (PBYI) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Puma Biotechnology, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Puma Biotechnology, Inc. (PBYI) Average Current Ratio

How has PBYI Current Ratio performed in the past?

The current Current Ratio of Puma Biotechnology, Inc. (PBYI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Puma Biotechnology, Inc. (PBYI) Current Ratio vs. Peers

How is PBYI’s Current Ratio compared to its peers?

Puma Biotechnology, Inc.’s Current Ratio is less than Ultragenyx Pharmaceutical Inc. (2.81), less than Crinetics Pharmaceuticals, Inc. (16.38), less than Arvinas, Inc. (4.17), less than Revolution Medicines, Inc. (14.24), less than Kura Oncology, Inc. (11.47), less than 2seventy bio, Inc. (4.95), less than Intercept Pharmaceuticals, Inc. (4.22), less than Iovance Biotherapeutics, Inc. (4.22), less than Sarepta Therapeutics, Inc. (3.84), less than Madrigal Pharmaceuticals, Inc. (5.98), less than Viking Therapeutics, Inc. (36.47), greater than Hepion Pharmaceuticals, Inc. (1.30), less than PTC Therapeutics, Inc. (2.10), less than Heron Therapeutics, Inc. (2.28), greater than Coherus BioSciences, Inc. (1.25), less than Larimar Therapeutics, Inc. (13.10), less than MacroGenics, Inc. (3.75),

Build a custom stock screener for Puma Biotechnology, Inc. (PBYI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Puma Biotechnology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Puma Biotechnology, Inc. (PBYI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Puma Biotechnology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.